MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that a planned futility interim analysis of the ...
Independent valuation analysis estimates post-Phase 3 asset value approaching USD 1 billion, and the current valuation with a ...
PH94B for Acute Treatment of Social Anxiety Disorder Did Not Meet Primary Endpoint PH94B Showed a Favorable Safety and Tolerability Profile among Study Participants that was Consistent with Prior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results